The treatment of multiple myeloma has changed dramatically in the last decade with
the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for
autologous stem cell transplantation (ASCT) are treated with non-alkylating agent–containing
regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone.
For patients not eligible for ASCT, the current standard of care is melphalan, prednisone,
and thalidomide. Ongoing trials will soon assess if combinations including melphalan
and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive
option. Patients who have risk factors, such as deletion 13 or translocation t(4;14)
or t(14;16), are candidates for novel, more aggressive treatments.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Multiple myeloma.N Engl J Med. 2004; 351: 1860-1873
- Multiple myeloma: diagnosis and treatment.Mayo Clin Proc. 2005; 80: 1371-1382
- A long-term study of prognosis of monoclonal gammopathy of undetermined significance.N Engl J Med. 2002; 346: 564-569
- Prevalence of monoclonal gammopathy of undetermined significance.N Engl J Med. 2006; 354: 1362-1369
Ries LAG, Eisner MP, Kosary CL, et al, editors. SEER cancer statistics review, 1975–2000. Bethesda (MD): National Cancer Institute. Available at: http://seer.cancer.gov//csr/1975_2001. Accessed September 7, 2004.
- Review of 1,027 patients with newly diagnosed multiple myeloma.Mayo Clin Proc. 2003; 78: 21-33
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.Blood. 2005; 106: 35-39
- A randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs Dex + Placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM).Blood. 2006; 108: 3563
- Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial.Blood. 2006; 108: 57
- Thalidomide and hematopoietic-cell transplantation for multiple myeloma.N Engl J Med. 2006; 354: 1021-1030
- Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.J Clin Oncol. 2006; 24: 431-436
- Antitumor activity of thalidomide in refractory multiple myeloma.N Engl J Med. 1999; 341 ([see comments]): 1565-1571
- Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.J Clin Oncol. 2002; 20: 4319-4323
- Thalidomide alone or with dexamethasone for multiple myeloma.Blood. 1999; 94 (A 2686): 604a
- First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.Haematologica. 2004; 89: 826-831
- A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma.Blood. 2006; 108: 795
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma 10.1182/blood-2006-04-015909.Blood. 2006; 108: 3458-3464
- Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010).Blood. 2005; 106: 6
- Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009).Proceedings of the American Society of Clinical Oncology. 2006; 24: A7521
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.Blood. 2005; 106: 4050-4053
- Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival.Blood. 2006; 108: 798
- A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group.Blood. 2006; 108: 799
- A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med. 2003; 348: 2609-2617
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med. 2005; 352 ([see comment]): 2487-2498
- Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM).Blood. 2004; 104 (A336): 100a
- Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.Br J Haematol. 2005; 129: 776-783
- Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.Haematologica. 2006; 91: 1498-1505
- VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial.Blood. 2006; 108: 56
- A comparison of allografting with autografting for newly diagnosed myeloma.N Engl J Med. 2007; 356: 1110-1120
- Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.Blood. 2002; 99: 3163-3168
- Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.Blood. 2006; 108: 3289-3294
- First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6).Blood. 2006; 108: 58a
- Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.Blood. 2006; 107: 1292-1298
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.Blood. 2004; 104: 3052-3057
- Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma.J Clin Oncol. 2006; 24: 1a
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.Lancet. 2006; 367: 825-831
- Thalidomide and lenalidomide-associated thromboembolism among patients with cancer.JAMA. 2006; 296: 2559-2560
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study.Blood. 2006; 108: 2165-2172
- Oral revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: a phase I-II study.Blood. 2006; 108: 800a
- Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.Leukemia. 2006; 21: 151-157
- Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.Leukemia. 2006; 21: 164-168
- Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma 10.1182/blood-2005-09-3869.Blood. 2006; 107: 3474-3480
Article info
Footnotes
SVR has received research support to cover the cost of clinical trials at Mayo Clinic from Celgene Corporation. AP has received scientific advisory board and lecture fees from Pharmion, Celgene, and Janssen-Cilag. Also supported by grants CA 62242, CA107476, CA 100080, and CA 93842 from the National Cancer Institute, Bethesda, Maryland, USA to SVR. Supported in part by the Università degli Studi di Torino; Fondazione Neoplasie Sangue Onlus, Associazione Italiana Leucemie, Compagnia di S Paolo, Fondazione Cassa di Risparmio di Torino, Ministero dell'Università e della Ricerca (MIUR), and Consiglio Nazionale delle Ricerche (CNR); Italy.
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
